Clinical Research Directory
Browse clinical research sites, groups, and studies.
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
Sponsor: Cogent Biosciences, Inc.
Summary
The purpose of this expanded access program (EAP) is to provide investigational bezuclastinib so that it can be coadministered with sunitinib to patients with a diagnosis of gastrointestinal stromal tumors (GIST) with no comparable or satisfactory alternative therapy options. The combination of bezuclastinib and sunitinib provides broad inhibition of all primary and secondary KIT mutations that commonly occur in GIST.
Official title: Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
EXPANDED_ACCESS
Enrollment
Not specified
Start Date
Not specified
Completion Date
Not specified
Last Updated
2026-05-08
Healthy Volunteers
Not specified
Interventions
Bezuclastinib
Drug: Bezuclastinib
Sunitinib
Drug: Sunitinib (locally sourced)
Locations (18)
Mayo Clinic Hospital
Phoenix, Arizona, United States
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States
UCLA Department of Medicine- Hematology/Oncology
Los Angeles, California, United States
University of Colorado
Aurora, Colorado, United States
Smillow Cancer Hospital - Yale New Haven Health
New Haven, Connecticut, United States
Mayo Clinic
Jacksonville, Florida, United States
Orlando Health
Orlando, Florida, United States
The University of Chicago Medical Center
Chicago, Illinois, United States
Dana Farber Cancer Institute (DFCI)
Boston, Massachusetts, United States
Mayo Clinic
Rochester, Minnesota, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Taylor Cancer Research Center
Maumee, Ohio, United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
MD Anderson Cancer Center
Houston, Texas, United States
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States
Shenandoah Oncology
Winchester, Virginia, United States